Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 2/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802592 | 0.85 | GAA (0.38) | GAAHDAC1HDAC2HDAC8IKBKB | |
| SCHEMBL6800123 | 0.80 | LMNA (0.41) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL6803053 | 0.80 | MAPT (0.42) | HDAC1HDAC2HDAC8 | |
| SCHEMBL7246595 | 0.78 | CTSC (0.38) | GAAXIAPKDM4EPPARGNCOA2 | |
| SCHEMBL6799108 | 0.75 | GAA (0.37) | GAAIKBKBKDM4EPPARGNCOA2 | |
| SCHEMBL6801170 | 0.71 | HDAC1 (0.39) | GAAHDAC1HDAC2HDAC8KDM4E | |
| SCHEMBL6334543 | 0.70 | GAA (0.55) | GAAIKBKBKDM4EPPARGNCOA2 | |
| SCHEMBL6799385 | 0.69 | TP53 (0.39) | GAAKDM4EPPARGALDH1A1 | |
| SCHEMBL4741742 | 0.68 | IKBKB (0.57) | GAAIKBKBKDM4EPPARGNCOA2 | |
| SCHEMBL6800783 | 0.68 | RAB9A (0.36) | HDAC1HDAC2HDAC8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608057-B2 | Compounds useful as reversible inhibitors of cathepsin S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | claimed |
| US-20020091259-A1 | Compounds useful as reversible inhibitors of cathepsin S | CYWIN CHARLES L (US) | 2002-07-11 | — | — | US | claimed |
| US-6730671-B2 | ENZYME INHIBITOR TREATING AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20030158406-A1 | Compounds useful as reversible inhibitors of cathepsin S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-6395897-B1 | DRUGS FOR ENZYME INHIBITORS ANTICOAGULANTS AND TREATMENT OF AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091259-A1 | Compounds useful as reversible inhibitors of cathepsin S | CTSS, CTSB, CTSV | GAA 47/4885HDAC1 95/4885HDAC2 198/4885 |
| US-20030158406-A1 | Compounds useful as reversible inhibitors of cathepsin S | CTSS, CTSB, CTSV | GAA 47/4885HDAC1 95/4885HDAC2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.